Market News AIOpen the app

KTTA stock news · Pasithea Therapeutics Corp.

Stories about Pasithea Therapeutics Corp. (KTTA) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for KTTA

Follow Pasithea Therapeutics Corp. (KTTA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KTTA
Free on the App Store and Google Play, or on the web.
  1. Nov 14, 2026, 9:09 AM ET · Opinion

    HC Wainwright & Co. increased the price target for Pasithea Therapeutics to $4.00 from $3.00.

    Good for KTTA

    HC Wainwright raised its KTTA share target from $3 per share to $4 per share and kept its buy recommendation. This is favorable, but the story reports no new clinical results.

  2. Sep 18, 2026, 5:13 PM ET · Market

    On Friday evening, 12 health care stocks saw big changes in their prices.

    Neutral

    Pasithea Therapeutics stock declined 7.36% to $0.49 after-market. The report contains no business facts, so it does not change Pasithea's prospects.

  3. Sep 16, 2026, 4:15 PM ET · Market

    Pasithea Therapeutics Corp. says its warrants will stop trading on September 17, 2026.

    Neutral

    Pasithea said its warrants will expire and be delisted. The common stock keeps trading, so this administrative step leaves the company's outlook unchanged.

  4. Aug 21, 2026, 5:49 PM ET · Trouble

    Pasithea Therapeutics Corp. faces potential delisting after failing to meet ongoing listing standards; listing transfer initiated (KTTA).

    Bad for KTTA

    Pasithea Therapeutics Corp. has filed a Form 8-K indicating that it has received a notice of delisting due to failure to satisfy continued listing rules. This news is critical as it may lead to a significant decline in investor confidence and trading activity.